The American Journal of Managed Care (AJMC) recently caught up with McKesson Specialty Health’s Nicholas Robert to discuss some of the challenges and benefits of real-world evidence, as well as some of the challenges involved with variability in clinical practice.
Robert says real-world evidence and real-world data has opened the door for new strategies in the development cycle.
” … If we have the opportunity to develop a new treatment, especially if the cancer’s a rare cancer, it’s hard to do the standard randomized clinical trial,” Robert said. “So, what we can do is, that new agent can be tested in a group of new patients and we can compare those results with a similar group treated with standard therapy and in this way, we can advance new treatment faster.”
